| pubmed-article:16550574 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16550574 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:16550574 | lifeskim:mentions | umls-concept:C0021436 | lld:lifeskim |
| pubmed-article:16550574 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:16550574 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:16550574 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:16550574 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:16550574 | lifeskim:mentions | umls-concept:C0850292 | lld:lifeskim |
| pubmed-article:16550574 | lifeskim:mentions | umls-concept:C1134564 | lld:lifeskim |
| pubmed-article:16550574 | lifeskim:mentions | umls-concept:C1519810 | lld:lifeskim |
| pubmed-article:16550574 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:16550574 | pubmed:dateCreated | 2006-3-27 | lld:pubmed |
| pubmed-article:16550574 | pubmed:abstractText | Adjuvant hepatic arterial infusion (HAI) chemotherapy has been demonstrated to improve disease-free survival for colorectal cancer liver metastases. It is unclear if this improvement can be extrapolated to unresectable liver metastases that undergo RFA. The aim of this study was to evaluate the combination of RFA and HAI chemotherapy for unresectable liver metastases. | lld:pubmed |
| pubmed-article:16550574 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16550574 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16550574 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16550574 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16550574 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:16550574 | pubmed:issn | 0022-4790 | lld:pubmed |
| pubmed-article:16550574 | pubmed:author | pubmed-author:McMastersKell... | lld:pubmed |
| pubmed-article:16550574 | pubmed:author | pubmed-author:MartinRobert... | lld:pubmed |
| pubmed-article:16550574 | pubmed:author | pubmed-author:ScogginsCharl... | lld:pubmed |
| pubmed-article:16550574 | pubmed:copyrightInfo | (c) 2006 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:16550574 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16550574 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16550574 | pubmed:volume | 93 | lld:pubmed |
| pubmed-article:16550574 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16550574 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16550574 | pubmed:pagination | 387-93 | lld:pubmed |
| pubmed-article:16550574 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:meshHeading | pubmed-meshheading:16550574... | lld:pubmed |
| pubmed-article:16550574 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16550574 | pubmed:articleTitle | A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy. | lld:pubmed |
| pubmed-article:16550574 | pubmed:affiliation | Department of Surgery, Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, KY 40202, USA. Robert.martin@louisville.edu | lld:pubmed |
| pubmed-article:16550574 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16550574 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16550574 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:16550574 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
